ConductScience.org, home
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
API referenceFor AI assistants

Trial · NCT02538666

Adverse events2,052

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 2,052

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherAnaemiaBlood and lymphatic system disordersGlobal Placebo31273
otherAnaemiaBlood and lymphatic system disordersGlobal Nivolumab 240 mg30279
otherAnaemiaBlood and lymphatic system disordersGlobal Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg25278
otherAnaemiaBlood and lymphatic system disordersChina Placebo1026
otherAnaemiaBlood and lymphatic system disordersChina Nivolumab 240 mg425
otherAnaemiaBlood and lymphatic system disordersChina Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg1224
otherLeukocytosisBlood and lymphatic system disordersGlobal Placebo0273
otherLeukocytosisBlood and lymphatic system disordersGlobal Nivolumab 240 mg0279
otherLeukocytosisBlood and lymphatic system disordersGlobal Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg0278
otherLeukocytosisBlood and lymphatic system disordersChina Placebo026
otherLeukocytosisBlood and lymphatic system disordersChina Nivolumab 240 mg125
otherLeukocytosisBlood and lymphatic system disordersChina Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg224
otherLeukopeniaBlood and lymphatic system disordersGlobal Placebo4273
otherLeukopeniaBlood and lymphatic system disordersGlobal Nivolumab 240 mg6279
otherLeukopeniaBlood and lymphatic system disordersGlobal Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg2278
otherLeukopeniaBlood and lymphatic system disordersChina Placebo326
otherLeukopeniaBlood and lymphatic system disordersChina Nivolumab 240 mg225
otherLeukopeniaBlood and lymphatic system disordersChina Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg324
otherNeutropeniaBlood and lymphatic system disordersGlobal Placebo5273
otherNeutropeniaBlood and lymphatic system disordersGlobal Nivolumab 240 mg8279

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02538666/events

API referenceFor AI assistants